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Abstract
Background: Runx transcription factors play critical roles in the developmental control of cell fate
and contribute variously as oncoproteins and tumor suppressors to leukemia and other cancers.
To discover fundamental Runx functions in the cell biology of animal development, we have
employed morpholino antisense-mediated knockdown of the sea urchin Runx protein SpRunt-1.
Previously we showed that embryos depleted of SpRunt-1 arrest development at early gastrula
stage and underexpress the conventional protein kinase C SpPKC1.
Results: We report here that SpRunt-1 deficiency leads to ectopic cell proliferation and extensive
apoptosis. Suppression of the apoptosis by pharmacological inhibition of caspase-3 prevents the
ectopic proliferation and rescues gastrulation, indicating that many of the overt defects obtained
by knockdown of SpRunt-1 are secondary to the apoptosis. Inhibition or knockdown of SpPKC1
also causes apoptosis, while cell survival is rescued in SpRunt-1 morphant embryos coinjected with
SpPKC1 mRNA, suggesting that the apoptosis associated with SpRunt-1 deficiency is caused by the
deficit in SpPKC1 expression. Chromatin immunoprecipitation indicates that SpRunt-1 interacts
physically with SpPKC1 in vivo, and cis-regulatory analysis shows that this interaction activates
SpPKC1 transcription.
Conclusions: Our results show that Runx-dependent activation of SpPKC1 is essential for
maintaining protein kinase C activity at levels conducive to cell survival during embryogenesis.

Background
The Runt domain (Runx) is a highly conserved 128 amino
acid sequence that defines a metazoan family of sequencespecific DNA binding proteins important for the developmental control of cell fate [1]. Vertebrates have three Runx
genes that are essential for the development of specific tissues (blood, bone, and proprioceptive neurons of the dor-

sal root ganglia, respectively, for Runx1, Runx2, and
Runx3), each of which is associated with leukemogenic or
carcinogenic mutations [1-4]. Some of these mutations
cause loss of Runx function while others are gain-of-function; hence, mammalian Runx genes display attributes of
both tumor suppressors and proto-oncogenes [4]. Runx
proteins have been shown to regulate cell cycle transit via
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their function as context-dependent transcriptional regulators. For example, Runx1 stimulates the G1 to S phase
transition in cultured mammalian cells, which may in
part reflect its transcriptional activation of cyclin D3 [5-7].
Runx1 is also an transactivator of the p14ARF tumor suppressor [8], while both Runx1 and Runx2 are transcriptional repressors of the p21Cip1/Waf1 cyclin-dependent
kinase inhibitor [9,10]. These findings indicate that Runx
is a critical node in the gene regulatory network that controls cell proliferation and/or survival during animal
development. Since many of the core linkages in this network are likely to be conserved throughout animal evolution, identification and cis-regulatory analysis of relevant
Runx target genes in experimentally tractable animal
models should help illuminate how Runx genes contribute to human development and health.
The sea urchin embryo is optically accessible and highly
amenable to experimental manipulations such as gene
transfer and morpholino antisense mediated knockdown,
making it a useful system for discovering fundamental
roles played by Runx proteins in the cell biology of animal
development. Whole genome sequence data [11] as well
as genomic Southern blot analysis [12] suggest that, contrary to previous reports [13-15], the sea urchin Strongylocentrotus purpuratus has two Runx genes (A. Poustka,
personal communication; AJR and JAC, unpublished
results). Only one of these (SpRunt-1, previously referred
to as SpRunt) is expressed in the embryo [12,14]. SpRunt1 is required for embryogenesis beyond blastula stage [16]
and contributes to transcriptional activation of the CyIIIa
actin gene, a marker of aboral ectoderm differentiation
[12]. SpRunt-1 mRNA is expressed globally in the early
embryo, whereas in the larva it accumulates predominantly in oral ectoderm and endomesoderm, tissues associated with continued growth and cell proliferation [14].
Embryos depleted of SpRunt-1 by morpholino antisense
oligonucleotides (MASOs) that sequence-specifically
block either translation or pre-mRNA splicing fail to gastrulate normally, display global defects in cell differentiation and proliferation and underexpress a number of
genes including that encoding the conventional protein
kinase C SpPKC1 [16].
Here we provide evidence that the gastrulation defect and
abnormal proliferation associated with SpRunt-1 deficiency are secondary effects of extensive apoptosis that
occurs in the post-blastula stage embryo. We further demonstrate that apoptosis is caused by a deficit in SpPKC1
activity, and that cell survival in SpRunt-1 morphant
embryos can be rescued by exogenous SpPKC1 mRNA.
Finally, we show that the SpPKC1 promoter region contains SpRunt-1 target sequences that are required for its
transcriptional activation.

http://www.biomedcentral.com/1741-7007/3/18

Results and Discussion
SpRunt-1 deficiency leads to apoptosis and secondary
proliferation
To characterize further the abnormal cell proliferation
associated with SpRunt-1 deficiency [16], gastrula stage
embryos injected with either a nonspecific control MASO
or the splice-blocking SpRunt-1 MASO were pulse-labelled
with bromodeoxyuridine (BrdU). The embryos were
fixed, and an anti-BrdU antibody was used to detect BrdU
incorporation, which is indicative of DNA synthesis during the labelling period. Normal late gastrula stage
embryos (Figure 1A) contained very few cells in S phase,
as shown by an absence of nuclear BrdU signal in the controls (Figure 1C). In contrast, SpRunt-1 morphant
embryos of the same age (Figure 1B) displayed extensive
nuclear BrdU incorporation throughout the embryo (Figure 1D; 11/14 imaged embryos with phenotypes similar
to that shown), indicating an abnormally high number of
proliferating cells, in agreement with our previous cytometric DNA analysis of cell cycle distribution in these
embryos [16].

Paradoxically, SpRunt-1 morphant embryos had about
half as much DNA per embryo as gastrula stage controls of
the same age [16]. Since deregulated cell proliferation is
often associated with programmed cell death [17-19], we
asked whether cells in SpRunt-1 morphants undergo
apoptosis, which could account for these embryos displaying lower than normal DNA content despite having
ectopic cell cycles. Terminal transferase-mediated dUTP
nick end labeling (TUNEL) showed that, in contrast to
controls (Fig. 1E), SpRunt-1 morphants displayed extensive DNA fragmentation (Figures 1F, 2B; 20/23 imaged
embryos with phenotypes similar to that shown), a hallmark of apoptosis. Apoptosis was further indicated by the
observation that SpRunt-1 morphants contained elevated
levels of activated caspase-3 (Figure 1H; compare with
control in Figure 1G) and caspase-6 (data not shown). The
apoptosis was specifically caused by SpRunt-1 deficiency,
as cell survival is rescued by coinjection of full-length
SpRunt-1 mRNA with the splice-blocking SpRunt-1 MASO
(Figure 2C). Interestingly, RNAi-mediated knockdown of
the Drosophila Runx gene CG15455 was recently shown to
lead to the apoptosis of in vitro cultured cells [20]; combined with our data this suggests an evolutionarily fundamental role for Runx genes in the control of metazoan cell
survival.
Ectopic cell cycles in the Drosophila eye disc lead to compensatory apoptosis via Jun kinase (JNK) signaling [19].
We hypothesized that apoptosis in SpRunt-1 morphant
embryos might similarly be a secondary response to
unregulated cell proliferation, in which case inhibiting
apoptosis might allow unbridled cell proliferation leading
to a tumor-like overgrowth phenotype. To test this we
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h)
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1 antisense-mediated knockdown of SpRunt-1 leads to ectopic proliferation and apoptosis in the gastrula stage (48
Morpholino antisense-mediated knockdown of SpRunt-1 leads to ectopic proliferation and apoptosis in the
gastrula stage (48 h) embryo. (A-B) Differential interference contrast (DIC) images of embryos injected with (A) control
MASO and (B) SpRunt-1 MASO. (C-D) Confocal micrographs (single optical sections) of BrdU-labeled embryos injected with
(C) control MASO and (D) SpRunt-1 MASO. (E-F) Confocal sections of TUNEL (green)- and DAPI (blue, DNA stain)-labeled
embryos injected with (E) control MASO and (F) SpRunt-1 MASO. (G-H) Confocal sections of antiactivated caspase-3 (green)and DAPI (blue)-labeled embryos injected with (G) control MASO and (H) SpRunt-1 MASO. Scale bar = 20 µm.
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by either injection of full-length SpRunt-1 mRNA, treatment with a casCell survival in SpRunt-1 morphant embryos is rescued by either injection of full-length SpRunt-1 mRNA, treatment with a caspase-3 inhibitor or injection of exogenous SpPKC1 mRNA. (A) DIC image of 48 h SpRunt-1 morphant
embryo. (B) Confocal section of 48 h SpRunt-1 morphant embryo labeled with DAPI (blue) and TUNEL (green). (C) Confocal
section of 48 h SpRunt-1 morphant embryo that was coinjected with full-length SpRunt-1 mRNA and then labeled with DAPI
and TUNEL as in (B). All of the imaged embryos (6/6) from this group had the TUNEL-negative phenotype shown, and 12/12
imaged embryos in a separate rescue experiment were similarly TUNEL-negative. (D) DIC image of 48 h SpRunt-1 morphant
embryo, from same set of injected embryos as that shown in (A) but treated with the caspase-3 inhibitor Ac-DEVD-CHO. (E)
Confocal section of 48 h SpRunt-1 morphant embryo treated with Ac-DEVD-CHO and then labeled with DAPI and TUNEL as
in (B). In a separate experiment, the frequency of imaged Ac-DEVD-CHO-treated morphants displaying a TUNEL-negative
phenotype similar to that shown here was 11/21, similar to the frequency of morphants displaying rescued gastrulation (Table
1). (F) DIC image of 48 h embryo injected with SpRunt-1 MASO + SpPKC1 mRNA. (G) Confocal section of 48 h embryo
injected with SpRunt-1 MASO + SpPKC1 mRNA and then labeled with DAPI and TUNEL as in (B). Arrows point to invaginated
guts, which are outlined in (C), (E) and (G).
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Table 1: Rescue of gastrulation in SpRunt-1 morphants by Ac-DEVD-CHO. Embryos injected with SpRunt-1 MASO were divided into
two groups, one of which was treated with Ac-DEVD-CHO as described in the Methods. At 48 h the embryos were observed under a
stereomicroscope and scored as gastrulation defective (with a typical morphant phenotype similar to that depicted in Figure 2A),
rescued gastrulation (with guts but no skeletons, a phenotype similar to that depicted in Figure 2D), or normal (indistinguishable from
uninjected control embryos with skeletons). The latter group probably represents embryos that were under injected; note that this
particular experiment had an unusually high proportion of such embryos (which more typically are in the range of 10–15%).

Treatment

Gastrulation defective

Rescued Gastrulation

Normal

SpRunt-1 MASO alone (n = 259)
SpRunt-1 MASO + Ac-DEVD-CHO
(n = 158)

162 (63%)
59 (37%)

55 (35%)

97 (37%)
44 (28%)

used the caspase-3 inhibitor acetyl-Asp-Glu-Val-Asp-CHO
(Ac-DEVD-CHO). Surprisingly, this drug rescued gastrulation (but not other aspects of development such as skeletogenesis) in about half of the SpRunt-1 morphants,
allowing development of more normal looking embryos
with fully invaginated guts (Figure 2D and Table 1). The
rescued embryos displayed negligible apoptosis when
assayed by TUNEL (Figure 2E), confirming the drug's efficacy in inhibiting caspase activity and suggesting that
apoptosis is a principal cause of the gastrulation defect
associated with SpRunt-1 deficiency. Apoptosis is also
likely to be the underlying cause of the ectopic proliferation observed in these embryos (rather than the converse), as SpRunt-1 morphants rescued with the caspase-3
inhibitor displayed negligible BrdU incorporation at late
gastrula stage, whereas SpRunt-1 morphants treated with
the DNA polymerase inhibitor aphidicolin (which blocks
cell proliferation while allowing for normal differentiation and morphogenesis from the mesenchyme blastula
stage on [21]) were not rescued from apoptosis [see Additional file 1]. It is likely that the ectopic cell cycles associated with SpRunt-1 deficiency are a regulative response to
a loss of embryo integrity, as occurs when cells from dissociated gastrula stage embryos re-enter the cell cycle [22].
Apoptosis associated with SpRunt-1 deficiency is caused by
loss of PKC expression
Protein kinase C (PKC) is a key component of numerous
developmental signalling pathways, and the conventional
PKC SpPKC1 was previously shown to be one of a number
of genes that are significantly underexpressed in SpRunt-1
morphant embryos [16]. Moreover, mammalian PKCα
promotes cell survival [23]. To ask whether the apoptosis
associated with SpRunt-1 deficiency might be caused by
the loss of PKC expression, we made use of chelerythrine,
a compound that selectively and completely inhibits
mammalian PKC activity at a concentration of ~10 µM
[24]. Embryos treated with 2–4 µM chelerythrine from the
mesenchyme blastula stage on (see Methods) displayed
gastrulation defects (Figure 3B) as well as extensive apoptosis as indicated by TUNEL (Figure 3G) and elevated lev-

els of activated caspase-3 (Figure 3L). A similar
gastrulation-defective phenotype (Figure 3D; 80/101
embryos) and cell survival defect (Figure 3I, N) was
obtained by injecting embryos with a MASO that targeted
the translation initiation codon of SpPKC1 mRNA. In
both cases cell survival (but not fully normal development) was rescued by treatment with the caspase-3 inhibitor (Figure 3C, H, E and 3J) despite the continued
presence of active caspase-3 (Figure 3M, O; note that the
inhibitor blocks the downstream activity of the activated
caspase).
These data strongly suggest that the deficit in SpPKC1
expression in SpRunt-1 morphants might be the underlying cause of their apoptotic phenotype, in which case
restoring SpPKC1 mRNA in these embryos should rescue
cell survival. To test this, we coinjected zygotes with the
SpRunt-1 MASO along with synthetic capped mRNA
encoding SpPKC1. Unlike embryos injected with the
SpRunt-1 MASO alone, most of the morphants coinjected
with solutions containing 400–800 ng/µl of SpPKC1
mRNA gastrulated (Figure 2F and Table 2) and displayed
negligible TUNEL signal (Figure 2G), indicating that
underexpression of PKC is indeed the principal underlying cause of the apoptosis and resulting gastrulation
defects associated with SpRunt-1 deficiency.
SpRunt-1 target sequences in the SpPKC1 promoter
region are required for transcriptional activation
Our findings raised the question of whether the requirement for SpRunt-1 in support of PKC expression is direct
or indirect. Examination of the 5' flanking sequence of the
SpPKC1 gene revealed the presence of two sequences that
match the Runx target consensus within 1.7 kb of the first
exon (Figure 4A and [see Additional file 2]). Fluorescently-labeled oligonucleotide probes representing each
of these sites bound sequence-specifically to recombinant
SpRunt-1 in an electrophoretic mobility shift assay
(EMSA; Figure 4B). Furthermore, sequences from the
SpPKC1 promoter region were specifically recovered by
chromatin immunoprecipitation (ChIP) using an anti-
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Figure 3 or knockdown of PKC leads to apoptosis that is suppressed by inhibition of caspase-3
Inhibition
Inhibition or knockdown of PKC leads to apoptosis that is suppressed by inhibition of caspase-3. (A-E) DIC
images, (F-J) fluorescent confocal images of embryos subjected to TUNEL (green) and counterstained with DAPI (blue) and (KO) immunofluorescent confocal images of embryos stained for activated caspase-3 (green) and counterstained with DAPI
(blue). (A), (F) and (K) are control embryos; (B), (G) and (L) are embryos treated with the PKC inhibitor chelerythrine from
mesenchyme blastula stage; (C), (H) and (M) are embryos treated with chelerythrine and the caspase-3 inhibitor Ac-DEVDCHO; (D), (I) and (N) are embryos injected with a SpPKC1 MASO; (E), (J) and (O) are embryos injected with the SpPKC1
MASO and treated with Ac-DEVD-CHO. The high levels of activated caspase-3 staining in panels (M) and (O) suggest that caspase-3 has been processed as a result of initiation of the apoptotic program but remains proteolytically inactive because of the
presence of the inhibitor.

Table 2: Rescue of gastrulation in SpRunt-1 knockdown embryos by SpPKC1 mRNA. Zygotes were coinjected with SpRunt-1 MASO and
varying amounts of SpPKC1 mRNA in two different experiments. At 48 h embryos were observed under a stereomicroscope and
scored for successful gastrulation (fully invaginated guts, with a phenotype similar to that depicted in Figure 2F). The SpPKC1 [mRNA]
refers to the concentration of the injection solution, approximately 2–5 pl of which was injected into each zygote.

Experiment

SpPKC1 [mRNA] (ng/µl)

Successful Gastrulation

1

200
400
800

2/50 (4%)
13/50 (26%)
36/50 (72%)

2

0
200
400

15/120 (12.5%)
48/100 (48%)
138/155 (89%)
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SpPKC1
is a direct target of SpRunt-1
SpPKC1 is a direct target of SpRunt-1. (A) Schematic of the 5' flanking sequence of SpPKC1, showing locations and
sequences of the Runx consensus binding elements (underlined bases mutated for reporter gene studies). (B) EMSA of recombinant Runt domain (RD)-CBFβ heterodimers using probes consisting of target sequences from CyIIIa [12] and the distal and
proximal Runx sites from SpPKC1. A 100-fold excess of unlabeled CyIIIa sequence was used as a competitor to test the specificity of the interactions. "C", complex between Runt domain and probe; "FP", free probe. (C) Chromatin immunoprecipitation
(ChIP) from 48 h embryos using either an anti-SpRunt-1 [12] or nonimmune IgG. CyIIIa serves as a positive control, whereas histone H4 sequences (present as several hundred copies per haploid genome) serves as a negative control for specificity. (D) Relative normalized expression of wild-type (WT) PKC1-luc and mutant PKC1-luc, in which the proximal and distal Runx target sites
have been mutated individually or in combination to abolish SpRunt-1 binding (PM, DM, and PM+DM, respectively), expression
in control embryos and embryos injected with SpRunt-1 MASO. Fold difference in expression levels of each construct and of
the basal luciferase vector alone (V) compared to the WT construct was measured by quantitative RT-PCR [38]. Each bar represents the averages and standard deviations from three to five different experiments. (E) Pathway summarizing the experimental approaches and results showing that SpRunt-1 promotes cell survival via transcriptional activation of SpPKC1.
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SpRunt-1 antibody [12], indicating that SpRunt-1 is
bound in vivo to these sequences at gastrula stage (Figure
4C). To test the functionality of the Runx target sequences
in this region we constructed a luciferase reporter gene
linked to ~1.9 kb 5' flanking sequence (including the
endogenous promoter) of SpPKC1 (Figure 4A and [see
Additional file 2]). When introduced into embryos, this
sequence activated transcription of the reporter by
approximately threefold and in a SpRunt-1 dependent
fashion, as reporter expression was reduced to near baseline levels in SpRunt-1 morphant embryos (Figure 4D).
Moreover, base substitutions that eliminate either the
proximal or the distal Runx target sequences in the
SpPKC1 cis-regulatory domain similarly reduced activity
of the reporter, as did combined substitutions that eliminated both target sequences (Figure 4D), suggesting that
the two Runx sites function synergistically rather than
additively to activate transcription.
The relatively weak activation of the reporter conferred by
the 1.9 kb SpPKC1 promoter fragment, together with our
previous results showing that endogenous SpPKC1 expression is reduced approximately seven fold in SpRunt-1 morphant embryos [16], suggests that there may be additional
enhancers outside of the 1.9 kb fragment that collaborate
with SpRunt-1 in activating transcription of the endogenous gene. Testing this possibility would require cis-regulatory analysis using a larger genomic fragment that
contains the SpPKC1 locus. Nevertheless, the data presented here support the proposition that the direct interaction of SpRunt-1 with its target sequences in the SpPKC1
cis-regulatory domain is required for normal levels of
SpPKC1 transcription in the post-blastula stage embryo,
which in turn is required to maintain PKC activity at levels
sufficient to antagonize caspase activity and suppress
apoptosis (Figure 4E).

Conclusions
Our results support the idea that, in animal development,
cells do not survive by default but rather by actively suppressing apoptosis in response to permissive cell signalling [25,26]. Furthermore, we find that deregulated
apoptosis can lead to secondary cell proliferation, similar
to the compensatory cell proliferation described by others
[27,28]. In contrast to the latter phenomenon however,
we do not observe overproliferation caused by apoptotic
cell signalling in the caspase-3 inhibited embryos. While
the specific role of SpPKC1 in suppressing apoptosis is not
known, there are several plausible pathways based on
well-known functions of mammalian PKCα, most notably its role in phosphorylating and thereby activating the
anti-apoptotic protein Bcl-2. [29-31]. Identification of the
relevant substrate(s) and pathway(s) in sea urchins awaits
further analysis, as does the basis for the secondary proliferation observed in SpRunt-1 morphants.

http://www.biomedcentral.com/1741-7007/3/18

In addition to the conventional PKCs (cPKCs), the PKC
family also includes non-conventional and atypical PKCs
(nPKCs and aPKCs, respectively) [32]. We do not yet
know how many PKC family members are in S. purpuratus,
although available expressed sequence tag (EST) and
genomic sequence data suggest that SpPKC1 is the only
cPKC gene expressed in the embryo, and possibly the only
cPKC gene encoded in the genome (JAC, unpublished
results). We note in closing that mammals have three
cPKC genes, PKCα, PKCβ, and PKCγ. PKCβ is actually proapoptotic in myeloid cells, and its gene was recently
shown to be directly activated by a human Runx homolog,
RUNX1 [33]. This suggests that Runx-mediated control of
cPKC gene expression may be a primitive conserved character (i.e., plesiotypic) in animals, whereas the functional
output of this interaction (cell death or survival) varies
with context, something that would bear on whether a
given Runx gene is an oncogene or tumor suppressor. It
will therefore be interesting to determine whether the
other mammalian cPKC genes are also direct Runx regulatory targets, and whether the Runx-dependency of cell survival in Drosophila [20] is a function of PKC.

Methods
Animals and gametes
Adult Strongylocentrotus purpuratus were purchased from
either Charles Hollahan (Santa Barbara, California, USA)
or Pat Leahy (Corona del Mar, California, USA). Gametes
were obtained by vigorous shaking of animals or by intracoelomic injection of 0.5 M KCl.
Morpholino antisense oligonucleotides
Morpholino antisense oligonucleotides (MASOs) were
purchased from GeneTools, LLC (Philomath, Oregon,
USA). Nonspecific control and splice-blocking SpRunt-1
(m5) MASOs were as described previously [16]. The
sequence of the SpPKC1 MASO, which targets the AUG
start
codon
of
SpPKC1
mRNA,
is:
CATCTCAAACGACGAATCCGACATT.
Microinjection and embryo culture
Microinjection of zygotes was carried out by the method
of McMahon et al. [34], essentially as described in Kirchhamer et al. [35]. MASO injection solutions contained
500 µM MASO and 120 mM KCl. Embryos were cultured
in artificial seawater at 15°C.
BrdU labeling and antibody staining
Late gastrula stage embryos (44 h) were incubated in 300
µg/ml BrdU (Sigma-Aldrich; St. Louis, Missouri, USA) for
four hours in artificial seawater (ASW) at 15°C then fixed
in 4% formaldehyde in ASW for 90 min on ice. After the
embryos were washed three times in ASW, they were
treated with 2 M HCl on ice for 30 min, neutralized in 100
mM Tris, pH 9.5, 100 mM NaCl for 2 min on ice, and
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washed three times in phosphate buffered saline containing 0.2% Tween-20 (PBST). The embryos were post-fixed
in 4% formaldehyde in PBST for 20 min on ice, and
washed three times in ice-cold PBST. BrdU was detected
by staining with an AlexaFluor 647-conjugated anti-BrdU
antibody (Molecular Probes, Eugene, Oregon, USA)
diluted 1:20 in PBST and incubated overnight at 4°C. Digital images were collected using a Leica TCS SP2 confocal
microscope.
Antibodies directed against activated caspases 3 and 6
were obtained from Calbiochem (San Diego, California,
USA). Embryos were stained with 5 µg/ml antibody in
PBST with 5% bovine serum albumin (BSA) overnight at
4°C and then washed three times in PBST. Antibody labeling was detected by staining with AlexaFluor 488 goat
anti-mouse IgG from Molecular Probes in PBST with 5%
BSA for 1 h at room temperature. Following three washes
in PBST and nucleic acid staining with 4',6-diamidino-2phenylindole (DAPI), the digital images were obtained
with the Leica TCS SP2 confocal microscope.
Terminal transferase-mediated dUTP nick end labeling
(TUNEL) assay
Late gastrula stage embryos (48 h) were fixed for 1 h in 4%
paraformaldehyde at 4°C and washed for 1 h in PBST.
Staining was performed using the In Situ Fluorescein
Detection of Cell Death Kit from Roche (Indianapolis,
Indiana, USA). Stained embryos were washed three times
in PBST and labeled once in DAPI. Digital images were
collected using a Leica TCS SP2 confocal microscope.
DNA quantitation by fluorometry
The DNA content of isolated nuclei was quantitated by
fluorometry as described previously [16].
Drug treatments
The caspase-3 selective inhibitor Ac-DEVD-CHO (BD Biosciences; San Jose, California, USA) was added to SpRunt1 morphant cultures at a final concentration of 50 µM at
the 1–2 cell stage.

The DNA polymerase inhibitor aphidicolin (SigmaAldrich) was added to SpRunt-1 morphant cultures at a
final concentration of 0.2–0.5 µg/ml at mesenchyme blastula stage (24 h post-fertilization).
The PKC inhibitor chelerythrine (Sigma-Aldrich) was
added to embryo cultures at concentrations ranging from
2–4 µM from the mesenchyme blastula stage on. Higher
concentrations tended to be embryonic lethal whereas
lower ones gave no phenotype at all. Since the efficacy of
the drug in producing the gastrulation-defective phenotype varied from culture to culture, the optimal concentration for producing the gastrulation-defective phenotype at
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a frequency close to 100% was determined empirically for
each experiment. For example, in one experiment, 85% of
embryos treated with 3.5 µM chelerythrine were viable
but gastrulation defective (the remaining 15% appearing
normal) whereas 100% of embryos treated with 4 µM
chelerythrine were viable but gastrulation defective. For
other cultures the effective dose for a similar effect was
somewhat lower.
Synthetic mRNAs
Full-length SpRunt-1 mRNA for rescue experiments was
synthesized as previously described [16]. SpPKC1 mRNA
for rescue experiments was obtained as follows: an EST
(National Center of Biotechnology Information (NCBI)
accession number CD290393) containing the SpPKC1
start codon was obtained by BLAST using the Genbank
entry of Lytechinus pictus PKC1 (Genbank:U02967; [36])
as a query sequence. The SpPKC1 coding sequence was
then assembled from the S. purpuratus genome traces
using the LpPKC1 sequence as a scaffold. The assembled
SpPKC1 sequence was used to design the following primers: GTGGATAATTTTTGCTGGATTTGCGCCTTGA, (forward; ends 13 bp upstream of start codon) and
GTTCTACAGACAGACTGGCACTAGCT (reverse; reverse
complement of stop codon underlined). These primers
were used in a reverse transcription (RT)- PCR reaction
using the Platinum Quantitative RT-PCR ThermoScript
One-Step System from Invitrogen (Carlsbad, California,
USA) and 200 ng total RNA (purified using the RNeasy
Mini Kit from Qiagen; Valencia, California, USA) from 60
h embryos. An amplicon of the expected size was gel purified and inserted to pGEM-T Easy (Promega; Madison,
Wisconsin, USA). Sequencing was performed to determine the insert orientation and also to confirm the identity of the PKC1 sequence. An Apa1-Spe1 restriction
fragment containing the full length SpPKC1 sequence
with some flanking sequence was then transferred into a
pBluescript (Stratagene; LaJolla, California, USA) expression construct containing the Xenopus BetaGlobin 3' UTR
and polyA sequence (pGloBlu) [16]. Pst1 was used to linearize the resulting construct for in vitro transcription of
SpPKC1 using the T7 mMessage Machine from Ambion
(Austin, Texas, USA).
Assembly of the SpPKC1 5' flanking sequence
A contiguous sequence of over 2,500 bases extending in
the upstream direction relative to the start codon of
SpPKC1 was assembled from trace sequences obtained
from the Sea Urchin Genome Project [11] using the ContigExpress program in the InforMax Vector NTI suite (Invitrogen). Genotrace [37], which supports the reassembly
of short spans of genomic DNA sequence from trace files,
was used to generate independently a contig for comparison with the manually assembled one in ContigExpress.
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The sequence was verified by PCR amplification from
genomic DNA (see below).
Electrophoretic mobility shift assay
Cy5 5'-modified oligonucleotides containing the Runx
target sequences from the SpPKC1 gene were used as
probes (see Additional file 2). The binding reaction contained 25 mM HEPES, pH 7.5, 75 mM NaCl, 10 mM
MgCl2, 0.5 mM EDTA, 1 mM DTT, 0.3 mg/ml BSA, 10 µg/
ml poly dIdC/dIdC and 8% glycerol. Approximately 10
nmol of purified recombinant protein was incubated for
15 min at room temperature with or without competitor
and then incubated an additional 15 min at room temperature upon addition of the probe. Specificity of binding
was determined by the addition of 100-fold molar excess
of unlabeled competitor DNA corresponding to Runx target sequence from CyIIIa [12]. DNA-protein complexes
were resolved on a 5% (w/v) nondenaturing polyacrylamide gel using 0.5× TBE running buffer at 150 V for 3 h at
room temperature. Gels were imaged on a Typhoon 8700
(APBiotech; Piscataway, New Jersey, USA).
Chromatin immunoprecipitation (ChIP)
Late gastrula stage embryos were dissociated into single
cells by a washing once in dissociation buffer (1 M glycine
pH 8, 2 mM EDTA) and then three times in calcium-free
ASW. The dissociated cells were resuspended in a hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10
mM KCl and protease inhibitors) and incubated for 15
min on ice. Igepal (10% solution) was then added to a
final concentration of 0.6%, and the suspension was vortexed to release nuclei. Nuclei were recovered by centrifugation and resuspended in 20 mM HEPES, pH 7.9, 40 mM
KCl, 0.1 mM EDTA, 1 mM DTT, 20% glycerol and protease inhibitor cocktail (Roche). Formaldehyde was then
added to a concentration of 1%, and the nuclear suspension was incubated for 10 min at room temperature to
crosslink the chromatin. After stopping the crosslinking
reaction with the addition of glycine to 125 mM, the
nuclei were recovered by centrifugation, resuspended in a
nuclear lysis buffer (50 mM Tris-HCl, pH 8.1, 10 mM
EDTA, 1% SDS and protease inhibitors) and sonicated
with a force empirically determined to produce chromatin
with an average fragment size of ~500 base pairs. The sonicated chromatin solution was then precleared with Staphylococcus aureaus protein A positive cells (Staph A) and
aliquoted.

Prepared aliquots of chromatin were diluted with immunoprecipitation (IP) buffer (16.7 mM Tris-HCl, pH 8.1,
167 mM NaCl, 1.2 mM EDTA, 1.1% Triton X-100, 0.01%
SDS and protease inhibitors) and incubated with equivalent amounts of either nonimmune or anti-SpRunt-1 IgG
overnight at 4°C. The antibody complexes were recovered
by precipitation with Staph A, and, following several
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washes of the precipitated Staph A with IP wash buffer
(100 mM Tris-HCl, pH 9, 500 mM LiCl, 1% NP-40, 1%
deoxycholic acid, and protease inhibitors), eluted with an
SDS elution buffer (50 mM NaHCO3, 1% SDS). Following RNAase A addition (to 33 µg/ml), crosslink reversal by
heat treatment (67°C for 5 h), ethanol precipitation and
proteinase K treatment (240 µg/ml for 2 h at 45°C), the
DNA from the immunoprecipitates was purified using the
QIAquick PCR purification Kit (Qiagen), and used as template in PCR reactions with the following primers: CyIIIa:
GTAGCACACGGAGAGATTGTGGGACAT (forward) and
GGATCGGGGTTAGAGTTACATTTGGCTT
(reverse);
SpPKC1: CGAAACACACCACCAGCAACTTGCA (forward)
and CCAATGGTCTTCAACACACACTTCGCTA (reverse);
and H4: GTCGAGGAAAAGGAGGAAAGGGACTCGGAA
(forward) and TGCTCGCAGTAGGTGACTGCATCACGGAT (reverse).
SpPKC1:luciferase reporter gene construction and analysis
A 2.1 kb fragment of the upstream region of SpPKC1 was
PCR amplified from genomic DNA, subcloned into
pGEM-TEasy (Promega), and sequenced (see Additional
file 2). The fragment was subsequently inserted into the
pGLII Luciferase reporter plasmid (Promega) to generate
the SpPKC1-Luc reporter. The primers used for PCR,
GGGGTACC TGCACCCAATCCACACCCACTAAGA (forward) and CGGG ATCCACTGTCAAGGCGCAAATCCAGCAA (reverse), contain Kpn1 and BamH1 sites,
respectively, which are compatible with the multiple cloning sequence in pGLII. The Quikchange Site Directed
Mutagenesis Kit (Stratagene) was used to mutate each of
the SpRunt-1 target sites within the SpPKC1-Luc reporter,
using primers with the following sequences: ATCTCACCATAACgAtATAATTAGGGTTAGGAA (distal site forward),
TTCCTAACCCTAATTATaTcGTTATGGTGAGAT
(distal site reverse), TCATTCCTTTACATTTACgttAGTAGAAGTCAA (proximal site forward) and TTGACTTCTACTaacGTAAATGTAAAGGAATGA
(proximal
site
reverse). The base substitutions introduced by these primers (shown in lower case) are known to abolish Runx
binding [12] and were verified by sequencing of the resulting clones. Expression of SpPKC1-Luc and each Runx-site
mutant was measured by quantitative real time RT-PCR
essentially as described previously [16], and normalized
to luciferase DNA content using the method of Revilla-iDomingo et al [38]. The primers used to detect luciferase
mRNA
were
GGGATTTCAGTCGATGTACACGTTCGTCACATCT (forward) and GGCATGCGAGAATCTGACGCAGGCAGTTCTAT (reverse).
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Additional material
Additional File 1
Supplemental Figure 1 – In SpRunt-1 morphant embryos, the caspase-3 inhibitor Ac-DEVD-CHO suppresses ectopic cell proliferation,
whereas the DNA polymerase inhibitor aphidicolon does not suppress
the apoptosis. (A-C) Gastrula stage embryos labeled with BrdU and
DAPI. (D-F) Gastrula stage embryos labeled with TUNEL and DAPI. (A
and D) Control MASO injected embryos. (B, C, E and F) SpRunt-1
MASO injected embryos. (C) Embryo treated with Ac-DEVD-CHO. (F)
Embryo treated with aphidicolin from mesenchyme blastula stage on (as
was the control embryo shown in D).
Click here for file
[http://www.biomedcentral.com/content/supplementary/17417007-3-18-S1.pdf]

Additional File 2
Supplemental Figure 2 – 5' flanking sequence from the SpPKC1 gene.
The sequence was assembled from overlapping trace sequences obtained
from the sea urchin genome [11], a sequenced clone derived from a PCR
amplicon (in boldface; primer sites at termini predicted from assembled
genomic traces) and an EST in the NCBI database (solid underlined
sequence) that matches the N terminus of LpPKC1 coding sequence
(96% identity, 142 residues). Dotted underlined sequence corresponds to
the 5' UTR of the full length LpPKC1 cDNA (which begins with the
sequence: ACGAACATTT). Runx target sequences used to make probes
for EMSA are highlighted in color (core in yellow, flanking sequences in
green); lower case letters indicate residues that vary between the
sequenced clone (shown) and the trace genome sequences. Coding
sequence is highlighted in grey. A putative non-canonical TATA box
located 25 bases upstream of the inferred transcriptional start site is highlighted in black.
Click here for file
[http://www.biomedcentral.com/content/supplementary/17417007-3-18-S2.doc]
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